Australia; NSW; VIC; SA
A combination of two antibodies which target and boost the immune system, have shown promising results against hard to treat solid tumours in an early-stage clinical trial. The drugs, called CS1002 and CS1003 (or nofazinlimab), were trialled in patients with multiple types of cancer, including melanoma, lung cancer and liver cancer. The trial which was split into three parts, found that of the 61 patients who received the drug in the third stage, 37.7% had a positive response. The study also found the drugs had a manageable safety profile. The authors say this early trial supports further assessment of the combination of drugs for the treatment of solid tumours.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
